XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

AIDS Channel
subscribe to AIDS newsletter

Latest Research : Infectious Diseases : AIDS

   DISCUSS   |   EMAIL   |   PRINT
OPAL : A New Technology to Boost Immunity Against HIV
Mar 1, 2005, 12:43, Reviewed by: Dr.

�We have invented a simple new technology to boost the ability of the immune system to fight chronic infections such as AIDS and Hepatitis C. This involves using a patient�s own blood treated with small overlapping proteins of the virus (called peptides),� Associate Professor Kent says.

 
Australian researchers have made a major discovery in the fight against AIDS, with the development of a novel, simple and safe technique for boosting the body�s immune response to deadly viruses like HIV, which is even effective against drug resistant forms of the disease.

Associate Professor Stephen Kent from the University of Melbourne�s Department of Microbiology and Immunology says the findings hold great promise for the treatment of HIV, other chronic viral infections, and drug resistant infections, which are becoming a major problem.

�We have invented a simple new technology to boost the ability of the immune system to fight chronic infections such as AIDS and Hepatitis C. This involves using a patient�s own blood treated with small overlapping proteins of the virus (called peptides),� Associate Professor Kent says.

The research will be published today in the Journal of Virology.

The researchers call the therapy Overlapping Peptide Pulsed Autologous Cells (OPAL).

They have been awarded National Health and Medical Research Council (NHMRC) funding of almost $500,000 to refine the technique so that it can be studied in humans.

�The ability to induce and expand the immune response across most or all parts of the virus is highly advantageous. Our results, which consistently demonstrated sharply enhanced immunity in vaccinated animals, suggest that this therapy could also work in humans.�

The researchers initially set out to develop a technique for measuring the effectiveness of a HIV vaccine. They first extracted blood from previously vaccinated animals and then coated the cells with HIV peptide markers (a technique which only takes an hour to complete).

In a normal situation, when HIV or any virus infects a cell, it leaves behind tell-tale markers or peptides on the cell surfaces which tell the immune system that the cell is infected. In this study, the researchers did not infect the animals with HIV, but rather created the illusion to the body that these cells were infected because they had the tell-tale markers (peptides) on their surface.

When they injected this peptide-coated blood back into the vaccinated animals they found that it triggered a huge immune response.

�When we analysed HIV-specific immunity in the weeks following the assays (peptide-coating), a marked enhancement of virus-specific immunity was induced,� Associate Professor Kent says.

�The technique was also effective for boosting the immune response to Hepatitis C peptides and we believe that it could be refined for many different viral infections and cancers. We have also shown it can be used to induce immune responses against drug resistant forms of HIV. The OPAL technique is simpler than current cell-based vaccine techniques which usually require isolation of rare specialised cells from blood.�

Associate Professor Kent led a dedicated team of scientists, Ms Socheata Chea, Dr Jane Dale and Dr Rob De Rose at the University of Melbourne�s Department of Microbiology and Immunology, and collaborated with colleague Dr Ian Ramshaw at the Australian National University�s John Curtin School of Medical Research.

Associate Professor Kent says there is an urgent need to develop simple methods to induce or enhance HIV-specific immunity to prevent or control the disease. �Our research is a major step forward in this regard.�

The researchers will now embark on a series of experiments to refine the technique to make it even more practical and generate even bigger responses. Associate Professor Kent�s group plans to begin human testing of the OPAL therapy in the next one to two years.
 

- University of Melbourne
 

University of Melbourne

 
Subscribe to AIDS Newsletter
E-mail Address:

 



Related AIDS News

Keeping A3G in action represents a new way to attack HIV
Fighting HIV With HIV Virus Itself
HIV exploits competition among T-cells
Harmless GB Virus type C (GBV-C) protects against HIV infection
Study defines effective microbicide design for HIV/AIDS prevention
HIV depends on human p75, study shows
Simplified treatment of HIV infection shows promise
Clinical trial evaluates first-line approaches for treating HIV
T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
B cells with special protein direct HIV to T cells


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us